FINWIRES · TerminalLIVE
FINWIRES

Leerink Partners Initiates Altimmune at Outperform With $10 Price Target

By

Altimmune (ALT) has an average rating of overweight and mean price target of $16.06, according to analysts polled by FactSet.

What else is happening in Research?